人乳头瘤病毒16型E6蛋白的天然变体在改变角质形成细胞分化和诱导p53降解的能力方面存在差异。
Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation.
作者信息
Stöppler M C, Ching K, Stöppler H, Clancy K, Schlegel R, Icenogle J
机构信息
Department of Pathology, Georgetown University School of Medicine, Washington, DC 20007, USA.
出版信息
J Virol. 1996 Oct;70(10):6987-93. doi: 10.1128/JVI.70.10.6987-6993.1996.
Abstract
Three naturally occurring variant human papillomavirus type 16 (HPV-16) E6 proteins, which contained amino acid substitutions predominantly near the N terminus, exhibited significant differences in their abilities to abrogate keratinocyte differentiation in response to serum and calcium and to induce the degradation of p53 in vitro. One variant surpassed the reference E6 protein in its ability to abrogate keratinocyte differentiation responses, whereas another showed a reduction in this activity. Interestingly, the biological activities of the HPV-16 E6 proteins and their abilities to induce p53 degradation in vitro were directly correlated. These results demonstrate that naturally occurring variants of HPV-16 differ in biological and biochemical properties which might result in differences in pathogenicity.
摘要
三种天然存在的16型人乳头瘤病毒（HPV - 16）E6蛋白，其氨基酸取代主要集中在N端附近，在体外消除角质形成细胞对血清和钙的分化反应以及诱导p53降解的能力上表现出显著差异。一种变体在消除角质形成细胞分化反应的能力上超过了参考E6蛋白，而另一种则表现出该活性降低。有趣的是，HPV - 16 E6蛋白的生物学活性与其在体外诱导p53降解的能力直接相关。这些结果表明，HPV - 16的天然变体在生物学和生化特性上存在差异，这可能导致致病性的差异。
相似文献
1
Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation.
J Virol. 1996 Oct;70(10):6987-93. doi: 10.1128/JVI.70.10.6987-6993.1996.
2
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
J Virol. 1996 Jul;70(7):4509-16. doi: 10.1128/JVI.70.7.4509-4516.1996.
3
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity.
J Virol. 1992 Jul;66(7):4201-8. doi: 10.1128/JVI.66.7.4201-4208.1992.
4
Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation.
Virology. 1997 Oct 27;237(2):296-306. doi: 10.1006/viro.1997.8778.
5
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.
J Virol. 1994 Sep;68(9):5698-705. doi: 10.1128/JVI.68.9.5698-5705.1994.
6
HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes.
Virology. 1999 May 10;257(2):383-96. doi: 10.1006/viro.1999.9675.
7
Activities of human papillomavirus 16 E6 natural variants in human keratinocytes.
J Med Virol. 2007 Nov;79(11):1751-60. doi: 10.1002/jmv.20978.
8
Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
Virology. 2002 Jan 20;292(2):309-20. doi: 10.1006/viro.2001.1263.
9
HPV-16 E7 protein bypasses keratinocyte growth inhibition by serum and calcium.
Carcinogenesis. 1998 Aug;19(8):1481-6. doi: 10.1093/carcin/19.8.1481.
10
Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Virology. 2002 Jul 20;299(1):72-87. doi: 10.1006/viro.2002.1502.
引用本文的文献
1
Why HPV16? Why, now, HPV42? How the discovery of HPV42 in rare cancers provides an opportunity to challenge our understanding about the transition between health and disease for common members of the healthy microbiota.
FEMS Microbiol Rev. 2024 Nov 23;48(6). doi: 10.1093/femsre/fuae029.
2
Decoding the Genetic and Structural Features of HPV16 E5 Oncogene in Cervical Cancer Isolates from Pakistan: A Pilot Study.
Iran Biomed J. 2023 Aug 23;27(6):388-96. doi: 10.61186/ibj.3884.
3
The polymorphism analysis and epitope predicted of Alphapapillomavirus 9 E6 in Sichuan, China.
Virol J. 2022 Jan 20;19(1):14. doi: 10.1186/s12985-021-01728-4.
4
New approach for genomic characterisation of equine sarcoid-derived BPV-1/-2 using nanopore-based sequencing.
Virol J. 2022 Jan 6;19(1):8. doi: 10.1186/s12985-021-01735-5.
5
Exploring the roles of HPV16 variants in head and neck squamous cell carcinoma: current challenges and opportunities.
Virol J. 2021 Nov 8;18(1):217. doi: 10.1186/s12985-021-01688-9.
6
Metabolic Reprogramming in Cancer: Role of HPV 16 Variants.
Pathogens. 2021 Mar 16;10(3):347. doi: 10.3390/pathogens10030347.
7
Human Papillomavirus 58 E7 T20I/G63S Variant Isolated from an East Asian Population Possesses High Oncogenicity.
J Virol. 2020 Mar 31;94(8). doi: 10.1128/JVI.00090-20.
8
Molecular characterisation of genital human papillomavirus among women in Southwestern, Nigeria.
PLoS One. 2019 Nov 4;14(11):e0224748. doi: 10.1371/journal.pone.0224748. eCollection 2019.
9
Human papillomavirus genome variants and head and neck cancers: a perspective.
Infect Agent Cancer. 2018 Apr 10;13:13. doi: 10.1186/s13027-018-0185-6. eCollection 2018.
10
Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development.
Sci Rep. 2015 Oct 28;5:15751. doi: 10.1038/srep15751.
本文引用的文献
1
Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Virology. 1995 Apr 1;208(1):111-20. doi: 10.1006/viro.1995.1134.
2
High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.
J Virol. 1996 Jul;70(7):4509-16. doi: 10.1128/JVI.70.7.4509-4516.1996.
3
Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups.
J Virol. 1993 Nov;67(11):6424-31. doi: 10.1128/JVI.67.11.6424-6431.1993.
4
The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations.
J Virol. 1993 Nov;67(11):6413-23. doi: 10.1128/JVI.67.11.6413-6423.1993.
5
Sequence variants of human papillomavirus type 16 from couples suggest sexual transmission with low infectivity and polyclonality in genital neoplasia.
J Infect Dis. 1993 Oct;168(4):803-9. doi: 10.1093/infdis/168.4.803.
6
Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins.
Mol Cell Biol. 1993 Aug;13(8):4918-27. doi: 10.1128/mcb.13.8.4918-4927.1993.
7
Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
J Virol. 1993 Jun;67(6):3111-7. doi: 10.1128/JVI.67.6.3111-3117.1993.
8
Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Proc Natl Acad Sci U S A. 1993 May 1;90(9):3988-92. doi: 10.1073/pnas.90.9.3988.
9
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells.
Oncogene. 1993 Apr;8(4):919-24.
10
Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53.
Mol Cell Biol. 1993 Feb;13(2):775-84. doi: 10.1128/mcb.13.2.775-784.1993.
Zotero 插件